TMEM185A: A Potential Drug Target and Biomarker for Fragile Sites and Folic Acid-Induced Dysplasia

Target Name: TMEM185A

NCBI ID: G84548

TMEM185A

TMEM185A: A Potential Drug Target and Biomarker for Fragile Sites and Folic Acid-Induced Dysplasia

Introduction

Fragile site mutations have been implicated in the development of various diseases, including some forms of cancer, neurodegenerative disorders, and autoimmune diseases. Folic acid, a crucial molecule for the development and maintenance of healthy DNA, has been shown to play a critical role in the regulation of gene expression and DNA replication. However, disruptions in folic acid homeostasis have been implicated in the development of many diseases, including those with fragile site mutations.

TMEM185A, a protein that belongs to the transmembrane subfamily of the protein family TMEM, has been identified as a potential drug target and biomarker for fragile site mutations. In this article, we will discuss the implications of TMEM185A as a drug target and biomarker, as well as its potential clinical applications.

TMEM185A: Structure and Function

TMEM185A is a 21 kDa protein that is expressed in various tissues and organs, including brain, heart, liver, and muscle. It is localized to the endoplasmic reticulum (ER) and appears to play a role in regulating the levels of intracellular proteins, including folic acid-conjugated proteins.

The protein is composed of a transmembrane domain and an intracellular domain. The transmembrane domain is responsible for maintaining the stability of the protein and for its interactions with other molecules, including folic acid and its transport vehicles. The intracellular domain is responsible for the protein's cytoplasmic localization and for its interactions with the endoplasmic reticulum.

TMEM185A has been shown to interact with various folic acid-conjugated proteins, including HDACs (hypoxia-inducible aromotropic domain-containing proteins) and SIRTIs (Sirtuin-like proteins). These interactions suggest that TMEM185A may play a role in regulating the levels of folic acid-conjugated proteins and in modulating their activity.

TMEM185A has also been shown to be involved in the regulation of cellular processes that are critical for the development and maintenance of tissues and organs. For example, TMEM185A has also been shown to be involved in the regulation of cell adhesion, migration, and invasion, as well as in the regulation of cellular signaling pathways that are involved in cell growth, survival, and reproduction.

TMEM185A as a Drug Target

The potential drug target for TMEM185A is the regulation of folic acid homeostasis and the modulation of cellular processes that are critical for the development and maintenance of tissues and organs. This is suggested by the protein's interactions with folic acid-conjugated proteins and its involvement in the regulation of cellular processes that are critical for the development and maintenance of tissues and organs.

TMEM185A may serve as a drug target by modulating the activity of folic acid-conjugated proteins, which are involved in various cellular processes that are critical for the development and maintenance of tissues and organs. For example, TMEM185A may modulate the activity of HDACs, which are known to play a role in the regulation of cellular processes that are critical for the development and maintenance of tissues and organs. This may result in the inhibition of

Protein Name: Transmembrane Protein 185A

The "TMEM185A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM185A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets